Umbilical cord blood: Current status and future directions

Vox Sanguinis

Volumn 100, Issue 1, 2011, Pages 150-162

  McKenna, D H ^a   Brunstein, C G ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cellular therapy; Haematopoietic stem cell; Umbilical cord blood

Indexed keywords

BLOOD BANK; CELL HOMING; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; MORTALITY; NATURAL KILLER CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REGENERATIVE MEDICINE; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL EXPANSION; SURVIVAL RATE; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ADULT; BLOOD BANKS; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELLS; FETAL BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INFANT, NEWBORN; LYMPHOCYTE SUBSETS; TRANSPLANTATION CONDITIONING;

EID: 78650370872     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01409.x     Document Type: Review

References (131)

1. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321:1174-1178
2. Broxmeyer HE: Biology of cord blood cells and future prospects for enhanced clinical benefit. Cytotherapy 2005; 7:209-218
3. Rubinstein P, Rosenfield RE, Adamson JW, et al. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993; 81:1679-1690
4. Unrelated Cord Blood Banks/Registries Annual Report: World Marrow Donor Association, 2008
5. International Standards for UCB Collection, Processing, Testing, Banking, Selection and Release, 4th edn. Omaha, NE, Foundation for the Accreditation of Cellular Therapy, 2010
6. AABB Standards for Cellular Therapy Product Services, 4th edn. Bethesda, MD, 2009
7. Draft Guidance for Industry and FDA Staff: Investigational new drug application (INDs) for minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications: Food and Drug Administration Center for Biologics Evaluation and Research, 2009
8. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335:157-166
9. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88:795-802
10. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337:373-381
11. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565-1577
12. Gluckman E, Rocha V: Cord blood transplant: strategy of alternative donor search. Springer Semin Immunopathol 2004; 26:143-154
13. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100:1611-1618
14. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112:4318-4327
15. Ohnuma K, Isoyama K, Ikuta K, et al. Cord blood transplantation from HLA-mismatched unrelated donors as a treatment for children with haematological malignancies. Br J Haematol 2001; 112:981-987
16. Arcese W, Guglielmi C, Iori AP, et al. Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia. Bone Marrow Transplant 1999; 23:549-554
17. Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999; 93:3662-3671
18. Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003; 102:4290-4297
19. Jacobsohn DA, Hewlett B, Ranalli M, et al. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia. Bone Marrow Transplant 2004; 34:901-907
20. Sawczyn KK, Quinones R, Malcolm J, et al. Cord blood transplant in childhood ALL. Pediatr Blood Cancer 2005; 45:964-970
21. Wall DA, Carter SL, Kernan NA, et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005; 11:637-646
22. Gluckman E, Rocha V: Cord blood transplantation for children with acute leukaemia: a Eurocord registry analysis. Blood Cells Mol Dis 2004; 33:271-273
23. Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97:2957-2961
24. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962-2971
25. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369:1947-1954
26. Vibhakar R, Radhi M, Rumelhart S, et al. Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome. Bone Marrow Transplant 2005; 36:855-861
27. Bhattacharya A, Slatter MA, Chapman CE, et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 2005; 36:295-299
28. Jaing TH, Hung IJ, Yang CP, et al. Rapid and complete donor chimerism after unrelated mismatched cord blood transplantation in 5 children with beta-thalassemia major. Biol Blood Marrow Transplant 2005; 11:349-353
29. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352:2069-2081
30. Fang J, Huang S, Chen C, et al. Umbilical cord blood transplantation in Chinese children with beta-thalassemia. J Pediatr Hematol Oncol 2004; 26:185-189
31. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350:1960-1969
32. Knutsen AP, Steffen M, Wassmer K, et al. Umbilical cord blood transplantation in Wiskott Aldrich syndrome. J Pediatr 2003; 142:519-523
33. Knutsen AP, Wall DA: Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. J Clin Immunol 2000; 20:466-476
34. Lee V, Li CK, Shing MM, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant 2000; 26:455-458
35. Miniero R, Rocha V, Saracco P, et al. Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord. Bone Marrow Transplant 1998; 22(Suppl 1):S78-S79
36. Adamkiewicz TV, Haight A, Mazur MA, et al. Unrelated cord blood transplantation in children with sickle cell disease: US Centers Experience. Blood 2005; 106:2044
37. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101:2137-2143
38. Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006; 135:362-366
39. Stein J, Garty BZ, Dror Y, et al. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr 2007; 166(7):663-666
40. Walters MC, Quirolo L, Trachtenberg ET, et al. Sibling donor cord blood transplantation for thalassemia major: Experience of the Sibling Donor Cord Blood Program. Ann N Y Acad Sci 2005; 1054:206-213
41. Martin PL, Carter SL, Kernan NA, et al. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 2006; 12:184-194
42. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344:1815-1822
43. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351:2265-2275
44. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276-2285
45. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104:3813-3820
46. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113:1631-1638
47. Eapen M, Rocha V, Scaradavou A, et al. Effect of stem cell source on transplant outcomes in adult patients with acute leukemia: a comparison of unrelated bone marrow, peripheral blood, and cord blood. Blood 2008; 112: abstr 151
48. Kumar P, Defor T, Brunstein C, et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol Blood Marrow Transplant 2008; 14:1394-1400
49. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007; 109:1322-1330
50. Rocha V, Aversa F, Labopin M, et al. Outcomes of unrelated cord blood and haploidentical stem cell transplantation in adults with acute leukaemia. Blood 2005; 106:92a
51. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110:3064-3070
52. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343-1347
53. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102:1915-1919
54. Barker JN, Weisdorf DJ, Wagner JE: Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med 2001; 344:1870-1871
55. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13:82-89
56. Cutler C, Yeap B, Kao G, et al. Double Umbilical Cord Blood Transplantation using reduced intensity conditioning: a single-centre experience. Bone Marrow Transplant 2008; 41:S23
57. De Lima M, McMannis JD, Saliba R, et al. Double cord transplantation with and without ex-vivo expansion. Blood 2008; 112:63
58. Horwitz ME, Morris A, Gasparetto C, et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008; 14:591-594
59. Michalet M, Le QH, Robin M, et al. Double cord blood cell hematopoietic stem cell transplantation after standard or reduced intensity conditioning: report of the SFGM-TC registry. Blood 2008; 112:688
60. Gutman JA, Leisenring W, Appelbaum FR, et al. Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol Blood Marrow Transplant 2009; 15:1122-1129
61. Kindwall-Keller TL, Hegerfeldt Y, Fu P, et al. Prospective phase ii study of the biologic assignment one vs. two umbilical cord blood transplant in the reduced intensity conditioning setting. Blood 2008; 112:684
62. Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27:256-263
63. Brunstein CG, Weisdorf DJ, Defor T, et al. Favorable leukemia-free survival (LFS) for adults and children undergoing myeloablative umbilical cord blood (UCB) transplantation with cyclophosphamide (CY), fludarabine (FLU) and total body irradiation (TBI): a single center analysis of 194 patients. Blood 2008; 112:682
64. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114:4293-4299
65. MacMillan ML, Weisdorf DJ, Brunstein CG, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113:2410-2415
66. Ponce D, Zheng J, Gonzales AM, et al. Disease-free survival after cord blood transplantation is not different to that after related or unrelated donor transplantation in patients with hematologic malignancies. Blood 2009; 114:906
67. Brunstein CG, Gutman JA, Defor TE, et al. Reduced relapse and similar progression-free survival after double umbilical cord blood transplantation: comparison of outcomes between sibling, unrelated adult and unrelated DUCB hematopoietic stem cell donors. Blood 2009; 114:276
68. Brunstein CG, Hippen KL, McKenna DH, et al. Adoptive transfer of umbilical cord blood-derived regulatory t cells to recipients of nonmyeloablative unrelated double UCB transplantation. Blood 2009; 114:513
69. Delaney C, Brashen-Stein C, Voorhies H, et al. Notch-mediated expansion of human cord blood progenitor cells results in rapid myeloid reconstitution in vivo following myeloablative cord blood transplantation. Blood 2008; 112:85
70. Rocha V, Rio B, Garnier F, et al. Reduced intensity conditioning regimen in single unrelated cord blood transplantation in adults with hematological malignant disorders. An Eurocord-Netcord and SFGM-TC Survey. Blood 2006; 108:897a
71. Komatsu T, Narimatsu H, Yoshimi A, et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol 2007; 86(1):49-54
72. Misawa M, Kai S, Okada M, et al. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow. Int J Hematol 2006; 83:74-79
73. Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10:3586-3592
74. Morii T, Amano I, Tanaka H, et al. Reduced-intensity unrelated cord blood transplantation (RICBT) in adult patients with high-risk hematological malignancies. Blood 2005; 106:444b
75. Yuji K, Miyakoshi S, Kato D, et al. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 2005; 11:314-318
76. Bradley MB, Satwani P, Baldinger L, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007; 40:621-631
77. Komatsu T, Narimatsu H, Yoshimi A, et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol 2007; 86:49-54
78. Miyakoshi S, Kami M, Tanimoto T, et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. Transplantation 2007; 84:316-322
79. Narimatsu H, Watanabe M, Kohno A, et al. High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan. Bone Marrow Transplant 2008; 41:753-756
80. Uchida N, Wake A, Takagi S, et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008; 14:583-590
81. Lim SH, Esler WV, Periman PO, et al. Reduced-intensity umbilical cord blood transplant for older adult patients. Bone Marrow Transplant 2008; 42:685-686
82. Majhail NS, Weisdorf DJ, Wagner JE, et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107:3804-3807
83. Brunstein CG, Setubal D, Tomblyn M, et al. Umbilical cord blood transplant after reduced intensity conditioning provides outcomes comparable HLA-matched siblings for patients with high risk and advanced acute myeloid leukemia. Blood 2006; 108:183a
84. Rodrigues CA, Canals C, Brunstein C, et al. Comparison of outcomes after unrelated cord blood transplantation and matched unrelated donor RIC transplantation for lymphoid malignancies - a Eurocord-Netcord Group/Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. Blood 2009; 114:276
85. Broxmeyer HE, Hangoc G, Cooper S, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A 1992; 89:4109-4113
86. Hows JM, Bradley BA, Marsh JC, et al. Growth of human umbilical-cord blood in long-term haematopoietic cultures. Lancet 1992; 340:73-76
87. Lansdorp PM, Dragowska W, Mayani H: Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med 1993; 178:787-791
88. Kelly SS, Sola CB, de Lima M, et al. Ex vivo expansion of cord blood. Bone Marrow Transplant 2009; 44:673-681
89. Lam AC, Li K, Zhang XB, et al. Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice. Transfusion 2001; 41:1567-1576
90. Madlambayan GJ, Rogers I, Purpura KA, et al. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess. Biol Blood Marrow Transplant 2006; 12:1020-1030
91. Robinson SN, Ng J, Niu T, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006; 37:359-366
92. Deutsch V, Hubel E, Kay S, et al. Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood. Br J Haematol 2010; 149:137-149
93. Peled T, Mandel J, Goudsmid RN, et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy 2004; 6:344-355
94. Delaney C, Varnum-Finney B, Aoyama K, et al. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 2005; 106:2693-2699
95. Pecora AL, Stiff P, Jennis A, et al. Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood. Bone Marrow Transplant 2000; 25:797-799
96. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002; 8:368-376
97. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16:232-236
98. Ratajczak J, Reca R, Kucia M, et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004; 103:2071-2078
99. Ratajczak MZ, Reca R, Wysoczynski M, et al. Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia 2004; 18:1482-1490
100. Broxmeyer HE, Hangoc G, Cooper S, et al. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci 2007; 1106:1-19
101. Broxmeyer HE, Kohli L, Kim CH, et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol 2003; 73:630-638
102. Bieback K, Kern S, Kluter H, et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22:625-634
103. Bieback K, Kern S, Kocaomer A, et al. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 2008; 18:S71-S76
104. Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200:123-135
105. Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103:1669-1675
106. Berger MJ, Adams SD, Tigges BM, et al. Differentiation of umbilical cord blood-derived multilineage progenitor cells into respiratory epithelial cells. Cytotherapy 2006; 8:480-487
107. Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005; 105:750-758
108. McKenna DH, Sumstad DJ, Brunstein CG, et al. cGMP Production of Umbilical Cord Blood-Derived T-Regulatory Cells in Support of a First in Human Clinical Trial. Cytotherapy 2010; 12(Suppl 1):19
109. Fehervari Z, Sakaguchi S: CD4+ Tregs and immune control. J Clin Invest 2004; 114:1209-1217
110. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057
111. Ruggeri A, de Latour RP, Rocha V, et al. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol 2008; 143:404-408
112. McKenna DH Jr, Sumstad D, Bostrom N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007; 47:520-528
113. Dalle JH, Menezes J, Wagner E, et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res 2005; 57:649-655
114. Gardiner CM, Meara AO, Reen DJ: Differential cytotoxicity of cord blood and bone marrow-derived natural killer cells. Blood 1998; 91:207-213
115. Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009; 113:5628-5634
116. Beziat V, Nguyen S, Lapusan S, et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009; 23:721-728
117. Micklethwaite KP, Savoldo B, Hanley PJ, et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010; 115:2695-2703
118. Okas M, Gertow J, Uzunel M, et al. Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation. J Immunother 2010; 33:96-105
119. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114:1958-1967
120. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306
121. Mohamadzadeh M, Luftig R: Dendritic cells: in the forefront of immunopathogenesis and vaccine development - a review. J Immune Based Ther Vaccines 2004; 2:1
122. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005; 17:163-169
123. Moldenhauer A, Nociari MM, Dias S, et al. Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes. Vox Sang 2003; 84:228-236
124. Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003; 26:374-383
125. Wong EC, Maher VE, Hines K, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001; 3:19-29
126. Hsu AK, Kerr BM, Jones KL, et al. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy. Biol Blood Marrow Transplant 2006; 12:855-867
127. Balan S, Kale VP, Limaye LS: A large number of mature and functional dendritic cells can be efficiently generated from umbilical cord blood-derived mononuclear cells by a simple two-step culture method. Transfusion 2010; DOI: 10.1111/j.1537-2995.2010.02706.x
128. Jiang H, van de Ven C, Baxi L, et al. Differential gene expression signatures of adult peripheral blood vs cord blood monocyte-derived immature and mature dendritic cells. Exp Hematol 2009; 37:1201-1215
129. Rubinstein P, Carrier C, Carpenter C, et al. Graft selection in unrelated placental/umbilical cord blood (PCB) transplantation: influence and weight of hla match and cell dose on engraftment and survival. Blood 2000; 96:588a
130. Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32:397-407
131. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13:1461-1468